beta

CMPS

Compass Pathways Plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Its focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. It is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and it is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. It is headquartered in London, UK, with offices in New York, USA. Its vision is a world of mental wellbeing.

Market Cap: 1.56 Billion

Primary Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET)

Website: compasspathways.com

Shares Outstanding: 39.9 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.0

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in Biotechnology

Ethical Flags

Longest drawdown: 172 trading days

From: 2020-12-23 To: 2021-06-15

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud